Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

161. Prostate Cancer: Screening

Prostate Cancer: Screening Final Update Summary: Prostate Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Is Prostate Cancer Screening Right For You? (794 KB, ) Prostate Cancer: Screening Release Date: May 2018 Recommendation Summary Population Recommendation Grade Men aged 55 to 69 years For men aged 55 to 69 years, the decision to undergo periodic prostate-specific (...) antigen (PSA)–based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results

2018 U.S. Preventive Services Task Force

162. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer.o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer.Open-label, randomised (...) of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint.Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy.In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk

2018 EvidenceUpdates

163. Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis

Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis Although the digital rectal examination (DRE) is commonly performed to screen for prostate cancer, there is limited data to support its use in primary care. This review and meta-analysis aims to evaluate the diagnostic accuracy of DRE in screening for prostate cancer in primary care settings.We searched MEDLINE, Embase, DARE (Database of Abstracts of Reviews of Effects), Cochrane (...) ; I2 = 99.4%). Pooled PPV was 0.41 (95% CI, 0.31-0.52; I2 = 97.2%), and pooled NPV was 0.64 (95% CI, 0.58-0.70; I2 = 95.0%). The quality of evidence as assessed with GRADE was very low.Given the considerable lack of evidence supporting its efficacy, we recommend against routine performance of DRE to screen for prostate cancer in the primary care setting.© 2018 Annals of Family Medicine, Inc.

2018 EvidenceUpdates

164. A Web-Based Intervention to Reduce Distress After Prostate Cancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings (PubMed)

A Web-Based Intervention to Reduce Distress After Prostate Cancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings Distress after prostate cancer treatment is a substantial burden for up to one-third of men diagnosed. Physical and emotional symptoms and health service use can intensify, yet men are reticent to accept support. To provide accessible support that can be cost effectively integrated into care pathways, we developed (...) a unique, Web-based, self-guided, cognitive-behavior program incorporating filmed and interactive peer support.To assess feasibility of the intervention among men experiencing distress after prostate cancer treatment. Demand, acceptability, change in distress and self-efficacy, and challenges for implementation in clinical practice were measured.A pre-post, within-participant comparison, mixed-methods research design was followed. Phase I and II were conducted in primary care psychological service

Full Text available with Trip Pro

2018 JMIR cancer

165. Hedgehog in prostate cancer explained (PubMed)

Hedgehog in prostate cancer explained 29854872 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Hedgehog in prostate cancer explained. 67-68 10.18632/oncoscience.405 Buttyan Ralph R The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Li Na N The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Massah Shabnam S The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 Androgen Receptors Gli (...) Hedgehog Steroid Receptors prostate cancer CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 12 2018 04 21 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854872 10.18632/oncoscience.405 405 PMC5978441 Eur J Cancer. 2006 Mar;42(4):437-45 16406505 Prostate. 2014 Oct;74(14 ):1400-10 25132524 Cancer Chemother Pharmacol. 2016 Dec;78(6):1297-1304 27826729 Cell Mol Life Sci. 2000 Nov;57(12 ):1720-31 11130178 Oncogene. 2018 Apr;37(17 ):2313-2325 29429990 Horm Cancer. 2014

Full Text available with Trip Pro

2018 Oncoscience

166. Germline genetic testing in prostate cancer – further enrichment in variant histologies? (PubMed)

Germline genetic testing in prostate cancer – further enrichment in variant histologies? 29854870 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Germline genetic testing in prostate cancer - further enrichment in variant histologies? 62-64 10.18632/oncoscience.403 Markowski Mark C MC Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21287, USA. Antonarakis Emmanuel S ES Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel (...) Cancer Center, Baltimore, MD 21287, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 03 29 2018 03 29 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854870 10.18632/oncoscience.403 403 PMC5978447 N Engl J Med. 2016 Aug 4;375(5):443-53 27433846 Cell. 2015 May 21;161(5):1215-1228 26000489 Eur Urol. 2017 Jul;72 (1):34-42 28259476 Cell. 2015 Nov 5;163(4):1011-25 26544944 Eur Urol. 2018 May;73

Full Text available with Trip Pro

2018 Oncoscience

167. Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer (PubMed)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with increased cardiovascular mortality and sudden cardiac death, with some events occurring early after initiation of ADT. Testosterone levels are inversely associated with corrected QT (QTc) interval duration; therefore, prolongation of QTc duration could be responsible for some of these events during ADT.To

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

168. Men feel physically and psychologically ill-prepared for prostate cancer surgery

Men feel physically and psychologically ill-prepared for prostate cancer surgery Men feel physically and psychologically ill-prepared for prostate cancer surgery Discover Portal Discover Portal Men feel physically and psychologically ill-prepared for prostate cancer surgery Published on 28 November 2017 doi: Following prostate cancer surgery men often experience physical changes, such as urinary incontinence and erectile dysfunction, causing negative emotions and distress. This review found (...) that men felt poorly prepared – psychologically and physically – for the changes they might experience after surgery. Surgery was often described as "life-changing", and men described worrying about their future. NICE recommend that men and their partners/carers are fully informed about prostate cancer treatment options and their possible complications, and are supported in decision-making. This includes having access to psychosexual support at any time. This global review represents the views of men

2018 NIHR Dissemination Centre

169. MRI scan before biopsy could detect more prostate cancer

MRI scan before biopsy could detect more prostate cancer MRI scan before biopsy could detect more prostate cancer Discover Portal Discover Portal MRI scan before biopsy could detect more prostate cancer Published on 7 March 2017 doi: In men with a raised prostate specific antigen (PSA) blood test, which can be a sign of prostate cancer, MRI scanning before standard biopsy could allow more targeted biopsies and increase diagnosis of medium and high-risk prostate cancer. In this NIHR-funded study (...) , 576 men with suspected prostate cancer received a multi-parametric (MP)-MRI scan in addition to transrectal ultrasound-guided (TRUS) biopsy. They also had template mapping (TPM) biopsy of the entire prostate to reliably diagnose cancer. Neither MP-MRI scan nor TRUS-biopsy were entirely accurate. However, if MP-MRI is used as an initial test, followed by TRUS-biopsy targeted at areas identified on the scan, 18% more cancers could be detected than by TRUS biopsy alone. It may also help avoid

2018 NIHR Dissemination Centre

170. Large ten-year trial on treatment of localised prostate cancer will aid management decisions

Large ten-year trial on treatment of localised prostate cancer will aid management decisions Large ten-year trial on treatment of localised prostate cancer will aid management decisions Discover Portal Discover Portal Large ten-year trial on treatment of localised prostate cancer will aid management decisions Published on 15 September 2016 doi: New, long-term research indicates that active monitoring, with prompt treatment if needed, may be a better option than radical surgery or radiotherapy (...) for many men who have prostate cancer if it’s confined to the prostate gland. In the ProtecT trial, after an average of ten years, few men died of prostate cancer and there was no difference in survival between men receiving active monitoring and those who had radical treatments (which caused unpleasant side effects). But active monitoring did increase the risk of cancer progressing or spreading to other parts of the body. Longer follow-up will help to fully understand the balance between treatments

2018 NIHR Dissemination Centre

171. Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone

Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone Discover Portal Discover Portal Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone Published on 27 September 2016 doi: The drug zoledronic acid delayed the onset of bone complications by two months in men with prostate cancer (...) strontium-89 to treat prostate cancer that has spread to the bone, but not zoledronic acid unless other treatment has failed due to costs. The branded version of zoledronic acid did not give value for money but cheaper generic versions, now available, could be a better use of NHS resources. Share your views on the research. Why was this study needed? Prostate cancer is the second most common cause of cancer deaths in men in the UK. Just over 10,000 men died from prostate cancer in 2009. The rate has

2018 NIHR Dissemination Centre

172. Apalutamide (Erleada) - prostate cancer

Apalutamide (Erleada) - prostate cancer Drug Approval Package: ERLEADA (apalutamide) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ERLEADA (apalutamide) This review package includes Clinical Study Reports as part of a pilot project. The Clinical Study Report section provides information for pivotal clinical trials, not for all studies in the application. Company: Janssen Biotech Application Number: 210951 Orig 1 Approval Date: 02/14/2018 Persons

2018 FDA - Drug Approval Package

173. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature (...) follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m2 for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases

Full Text available with Trip Pro

2018 EvidenceUpdates

174. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer (...) , by use of the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy Prostate scale (FACT-P), and the EuroQol (EQ-5D-5L) questionnaires. PRO analyses were an exploratory endpoint. Analyses were by intention-to-treat. Results from the first pre-planned interim analysis (Oct 31, 2016), are presented here. This ongoing study is registered with Clinicaltrials.gov, number NCT01715285.Between Feb 12, 2013, and Dec 11, 2014, 1199 patients were

2018 EvidenceUpdates

175. Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected Prostate Cancer Recurrence (PubMed)

Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected Prostate Cancer Recurrence Background: Multiple new systemic agents have been targeted to metastatic prostate cancer, with decreased progression of disease but no cure. Surgical management of metastatic disease has been gaining interest, primarily in the setting of high-risk prostatectomies. However, metastasis-directed surgical intervention has been employed in rare scenarios (...) dissection was carried out, with subsequent nadir of his prostate-specific antigen at 0.026. Conclusion: To our knowledge, this is the first report of salvage pelvic lymph node dissection after metastatic detection by fluciclovine PET/CT scan. Our patient experienced a complete biochemical response; however, it remains to be seen whether this will be a lasting response. Surgical resection of metastatic sites in prostate cancer offers a safe alternative to systemic therapy and avoids systemic side effects.

Full Text available with Trip Pro

2018 Journal of endourology case reports

176. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. (PubMed)

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had (...) not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostate cancer; men whose MRI results were not suggestive of prostate cancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men who received

2018 NEJM

177. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. (PubMed)

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality.The Cluster Randomized Trial of PSA Testing (...) for Prostate Cancer (CAP) included 419 582 men aged 50 to 69 years and was conducted at 573 primary care practices across the United Kingdom. Randomization and recruitment of the practices occurred between 2001 and 2009; patient follow-up ended on March 31, 2016.An invitation to attend a PSA testing clinic and receive a single PSA test vs standard (unscreened) practice.Primary outcome: prostate cancer-specific mortality at a median follow-up of 10 years. Prespecified secondary outcomes: diagnostic cancer

Full Text available with Trip Pro

2018 JAMA

178. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. (PubMed)

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. The optimal treatment for Gleason score 9-10 prostate cancer is unknown.To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated (...) between 2000 and 2013.Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy.The primary outcome was prostate cancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes.Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median ages were 61, 67.7, and 67.5 years; median follow-up was 4.2, 5.1, and 6.3 years, respectively. By 10 years

Full Text available with Trip Pro

2018 JAMA

179. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone

Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone | European Medicines Agency Search Search Menu Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Ongoing clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating (...) the use of the prostate cancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA's ( ) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate cancer patients. In this study 34.7% of patients treated with Xofigo, Zytiga and prednisone/prednisolone have died so far, compared with 28.2% of patients given placebo, Zytiga and prednisone

2018 European Medicines Agency - EPARs

180. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer (PubMed)

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer Randomized evidence for extreme hypofractionation in prostate cancer is lacking. We aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation in a phase 3 randomized trial.We analyzed the results of the first 75 patients in our (...) phase 3 trial, comparing 38 Gy relative biologic effectiveness (RBE) in 5 fractions (n = 46) versus 79.2 Gy RBE in 44 fractions (n = 29). Patients received proton radiation using fiducials and daily image guidance. We evaluated American Urological Association Symptom Index (AUASI), adverse events (AEs), and Expanded Prostate Index Composite (EPIC) domains. The primary endpoint of this interim analysis was the cumulative incidence of grade 2 (G2) or higher AEs. The randomized patient allocation

Full Text available with Trip Pro

2018 Advances in radiation oncology